Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03701399 · ClinicalTrials.gov registry record · Phase 3

Troriluzole in Adult Participants With Spinocerebellar Ataxia

A Phase 3 study of Spinocerebellar Ataxias and Spinocerebellar Ataxia Type 6, sponsored by Biohaven Pharmaceuticals.

Active
Registry status
Phase 3
Development phase
299
Enrollment target
20
Study locations

NCT03701399 is a Phase 3 study of Spinocerebellar Ataxias and Spinocerebellar Ataxia Type 6 that is active but no longer recruiting, run by Biohaven Pharmaceuticals. The registered enrollment target is 299 participants, below the 419-participant average among 5 other Spinocerebellar Ataxias trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03701399, a Phase 3 study of Spinocerebellar Ataxias and Spinocerebellar Ataxia Type 6, is active but no longer recruiting, sponsored by Biohaven Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
299 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to compare the efficacy of Troriluzole (200 mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).

Conditions Studied

Spinocerebellar Ataxias Spinocerebellar Ataxia Type 6 Spinocerebellar Ataxia Type 1 Spinocerebellar Ataxia Type 2 Spinocerebellar Ataxia Type 3 Spinocerebellar Ataxia Type 7 Spinocerebellar Ataxia Type 8 Spinocerebellar Ataxia Type 10

Interventions

  • DRUG Placebo
  • DRUG troriluzole

Study Locations (20)

California

  • CNS Trials - Long Beach
  • UCLA - Los Angeles
  • UCSF - San Francisco

Florida

  • University of Florida Health - Gainesville
  • Mayo Clinic Florida - Jacksonville
  • University of South Florida - Tampa

Illinois

  • Northwestern University - Chicago
  • University of Chicago - Chicago
  • Northwest Neurology, Ltd. - Rolling Meadows

Massachusetts

  • Massachusetts General Hospital - Boston
  • Beth Israel Deaconess Medical Center - Boston

Arizona

  • Barrow Neurological Institute - Phoenix

Colorado

  • University of Colorado Hospital - Aurora

Georgia

  • Emory - Atlanta

Maryland

  • Johns Hopkins Medicine - Lutherville

Trial Details

FieldValue
Enrollment Target 299 participants
Start Date 2019-03-08
Est. Completion 2026-06
Phase Phase 3

Sponsor

Biohaven Pharmaceuticals

12 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03701399

The ClinicalTrials.gov registry entry for NCT03701399 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 299 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 419-participant average among 5 other Spinocerebellar Ataxias trials with a reported enrollment target (29% lower). The listed sponsor is Biohaven Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Spinocerebellar Ataxias appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03701399 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT03701399 about?

NCT03701399 is a clinical study titled "Troriluzole in Adult Participants With Spinocerebellar Ataxia". The purpose of this study is to compare the efficacy of Troriluzole (200 mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).

What is the current status of trial NCT03701399?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 299 participants. The study started on 2019-03-08. Estimated completion is 2026-06.

What conditions does trial NCT03701399 study?

This clinical trial studies the following conditions: Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3.

What interventions are being tested in trial NCT03701399?

The interventions under investigation include: Placebo (DRUG), troriluzole (DRUG).

Who is sponsoring clinical trial NCT03701399?

This trial is sponsored by Biohaven Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03701399 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Spinocerebellar Ataxias

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Spinocerebellar Ataxias

All registered trials for this condition

Spinocerebellar Ataxia Type 6

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.